Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Privi Speciality Chemicals reported strong FY26 results with total income of Rs 2,583 crore, up 22% YoY. Q4 revenue was Rs 726 crore (up 15.5%). EBITDA grew 40% to Rs 665 crore with margin expansion of 342 bps to 25.8%, while PAT surged 75% to Rs 328 crore. The company generated operating cash flow of Rs 550 crore, invested Rs 320 crore in CAPEX, and reduced net debt by Rs 113 crore, bringing Net Debt/Equity to 0.62x. PRIGIV JV with Givaudan achieved positive PAT in Q4. The company is pursuing a 5k:1k vision targeting Rs 5,000 crore revenue and Rs 1,000 crore+ EBITDA by FY29-30, with plans for new products including Maltol, Ethyl Maltol, Furfural, and specialty molecules. A proposed merger of subsidiaries PFSPL and PBPL is planned to strengthen operations.
Strong operational performance with margin expansion and debt reduction signals improving profitability and financial health. The medium-term 5k:1k guidance provides growth visibility, though targets are management estimates subject to external factors.